Omeros (OMER) Tops Q1 EPS by 12c

Omeros (NASDAQ: OMER) reported Q1 EPS of ($0.51), $0.12 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $388 thousand versus the consensus estimate of $120 thousand.

At March 31, 2015, Omeros had cash, cash equivalents and short-term investments of $70.1 million.

"In the first quarter of 2015, we completed the controlled launch of Omidria, which was successful across all of the assessed parameters – product was quickly and efficiently received by the facilities, reimbursement was confirmed across Medicare Administrative Contractors, and the clinical response was uniformly positive," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "In April, we initiated the broad U.S. launch of Omidria, and are excited to be making this important product widely available to both ophthalmic surgeons and their patients. The commercialization of Omidria, together with the encouraging results in our Phase 2 OMS721 clinical trial in TMA patients and the anticipated re-initiation of our Phase 2 OMS824 clinical program for patients with Huntington's disease and schizophrenia, should provide a series of potentially value-driving milestones for Omeros throughout the remainder of 2015 and beyond."

For earnings history and earnings-related data on Omeros (OMER) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
• MetroCity Bankshares, Inc. (MCBS) Tops Q1 EPS by 4c